Biological E to start phase-III trials by January, license vaccine by summer

Disclosing this in Hyderabad on Monday, managing director Mahima Datla said the company is currently evaluating four different formulations depending on different antigen strengths in the phase I-II combined studies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3l2PGES
via IFTTT